Latest Articles
-
Why Is The St. Jude Acquistion A Risky Bet For Abbott?
The St. Jude acquisition announced by Abbott (NYSE:ABT) is expected to provide significant synergies and the much needed growth for Abbott. However, this merger sets off alarm bells for Abbott’s investors, as the company will have to take...
-
How Important Are Emerging Markets To Abbott?
Abbott derives approximately 50% of its sales from emerging markets. This is one key reason as to why Abbott’s sales are largely affected due to foreign currency fluctuations. The company’s sales declined by 8.3% or $1680 million in 2...
-
Why Is Abbott Acquiring St. Jude?
In one of the most prodigious health-care deals in recent memory, Abbott Laboratories (NYSE:ABT) entered into a definitive agreement to acquire St. Jude Medical (NYSE: STJ) for $25 billion. In this analysis, we analyse the key reasons as to why ...
-
What is Abbott’s Revenue And Gross Profit Breakdown?
See the links below for more information and analysis about Abbott: What’s Abbott’s Fundamental Value Based On Expected 2016 Results? By What Percentage Did Abbott’s Revenue & Gross Profits Grow In The Last 5 Years? ...
-
Abbott Earnings Review: Foreign Currency Effects Subdue An Otherwise Strong Operational Growth
Leading healthcare major, Abbott Laboratories (NYSE:ABT) reported its Q1 2016 earnings on April 20, 2016. Despite a strong operating growth, led by the established pharmaceutical division in key emerging markets, Abbott’s key metrics decli...
-
What Can We Expect From Abbott’s Q1’16 Earnings?
Leading healthcare major, Abbott Laboratories is set to announce its Q1 2016 results on April 20, 2016. A stronger U.S dollar (relative to emerging markets currencies) and a challenging economic environment in Venezuela had together weighed down ...
-
What’s Abbott’s Fundamental Value Based On Expected 2016 Results?
See the links below for more information and analysis about Abbott: What is Abbott’s Revenue And Gross Profit Breakdown? By What Percentage Did Abbott’s Revenue & Gross Profits Grow In The Last 5 Years? Notes:
-
How Has Abbott’s Revenue Mix Changed In The Last 5 Years?
Nutritional and diagnostics have become an increasingly important segment for Abbott over the last five years. Sales from pharmaceutical products declined in 2012 due to the spin-off of Abbott’s proprietary pharmaceutical drugs business i...
-
By What Percentage Did Abbott’s Revenue & Gross Profits Grow In The Last 5 Years?
See the links below for more information and analysis about Abbott: What’s Abbott’s Fundamental Value Based On Expected 2016 Results? What is Abbott’s Revenue And Gross Profit Breakdown? How Has Abbott’s Revenue M...
-
Currency Headwinds Take A Toll On Abbott’s Profitability In Q4: Abbott Earnings
Leading healthcare conglomerate, Abbott Laboratories (NYSE:ABT) posted weak Q4 2015 results on January 28th. Weak guidance for 2016, owing to currency headwinds, and lower than expected EPS of $0.62 induced an approximately 10% drop in the stock...
-
Currency Headwinds Likely To Affect Abbott’s Profitability In Q4’15, Though Further Margin Improvements To Be Expected
Leading medical device maker Abbott Laboratories (NYSE:ABT) is scheduled to report its Q4’15 earnings on January 28th. The company’s revenues in 2015 have been largely affected by currency headwinds throughout the year. However, Abbott saw stron...
-
Scenarios That Can Add To Abbott’s Value
We expect a significant upside to our price estimate for healthcare major Abbott (NYSE: ABT), if it succeeds in getting the FDA approval for commercialization of its fully dissolving heart stent, Absorb, in the U.S. by the end of 2016. Additiona...
-
Abbott’s Q3 Results, A Deeper Look: Strong International Growth and Margin Expansion Drove
Healthcare conglomerate Abbott Laboratories (NYSE:ABT) posted strong third quarter results in its recent release. The company’s underlying growth remains strong despite reported revenues being hammered by currency headwinds. As expected, a bulk o...
-
New Products, Emerging Markets to Drive Abbott’s Q3 Results
Abbott Laboratories (NYSE:ABT) is scheduled to report its third quarter results on October 21st. Despite being on the lookout for acquisition opportunities and investors’ insistence for pulling the trigger, the company’s dry streak in the M&A...
-
Abbott Posts Broadly Positive Results, Currency Headwinds Notwithstanding
Abbott Laboratories (NYSE:ABT) reported second-quarter sales of $5.2 billion, an increase of 2.2% as reported or 10.7% on an operational (constant currency) basis. Adjusting for both currency effects and acquisitions, sales were up by a respecta...
